TH‐C‐M100J‐09: MR Guided Focused Ultrasound (MRgFU) For The Treatmentment of Prostate Cancer: A Feasibility Study of Increasing Cellular Uptake of AS‐MDM2 in Vivo

L. Chen, P. Hachem, A. Hananel, Z. mu, L. Padovani, C. Mercier, L. Khor, H. Kwon, C. ma, Alan Pollack

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: MDM2 is an oncogene and overexpressed in 30–40% of prostate cancer. Antisense MDM2 oligonucleotide (AS‐MDM2) inhibits MDM2 expression, and enhances the effects of radiation and chemotherapy on prostate cancer. The purpose of this study is to investigate the feasibility of increasing the cellular uptake of AS‐MDM2 using MR guided High Intensity Focused Ultrasound (MRgFU). Materials and Methods: A HIFU system (InSightec ExAblate 2000) and a 1.5T MR scanner (GE) were used for this study. Human prostate cancer cells LNCaP 105, were grown orthotopically in the prostates of 11 nude mice. Extensive experiments were performed to determine the optimal MR parameters for target delineation and the optimal ultrasound parameters for animal treatment studies using an acoustic phantom. The mice bearing implanted prostate tumors (61±22mm3) were treated under general anesthesia using pulsed focused ultrasound with the output acoustic power of 4W, pulse width of 100msec and either 300 or 900 pulses in one sonication. The focal region is cigar shaped, about 2mm in diameter and 10mm in focal length. The focal peak was set within the target under the MR guidance. Two to four sonications were used to cover the whole tumor. Immediately after the treatment 0.1ml of AS‐MDM2, dissolved in PBS, was given by tail vein injection at doses 25mg/kg. After 24hr, the animals were sacrificed and tumors were removed. The expression levels of p53 proteins were analyzed by immunohistochemical staining. Results: Our preliminary results showed that the animals tolerated well the HIFU treatment. With 300 pulses per site in each sonication blood cell extravasation on H&E staining and an increase in p53 expression (5.0±2.4%) in the treated tumor bearing LNCaP cells were observed as compared to the control group (1.3 ± 0.5%). Conclusion: MRgFU can be used an alternative treatment modality for prostate cancer treatment.

Original languageEnglish (US)
Pages (from-to)2625
Number of pages1
JournalMedical Physics
Volume34
Issue number6
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Antisense Oligonucleotides
Feasibility Studies
Prostatic Neoplasms
Sonication
Acoustics
Prostate
Neoplasms
Staining and Labeling
Therapeutics
Radiation Effects
Oncogenes
Nude Mice
Tobacco Products
General Anesthesia
Pulse
Tail
Veins
Blood Cells
Drug Therapy
Control Groups

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

TH‐C‐M100J‐09 : MR Guided Focused Ultrasound (MRgFU) For The Treatmentment of Prostate Cancer: A Feasibility Study of Increasing Cellular Uptake of AS‐MDM2 in Vivo. / Chen, L.; Hachem, P.; Hananel, A.; mu, Z.; Padovani, L.; Mercier, C.; Khor, L.; Kwon, H.; ma, C.; Pollack, Alan.

In: Medical Physics, Vol. 34, No. 6, 2007, p. 2625.

Research output: Contribution to journalArticle

Chen, L. ; Hachem, P. ; Hananel, A. ; mu, Z. ; Padovani, L. ; Mercier, C. ; Khor, L. ; Kwon, H. ; ma, C. ; Pollack, Alan. / TH‐C‐M100J‐09 : MR Guided Focused Ultrasound (MRgFU) For The Treatmentment of Prostate Cancer: A Feasibility Study of Increasing Cellular Uptake of AS‐MDM2 in Vivo. In: Medical Physics. 2007 ; Vol. 34, No. 6. pp. 2625.
@article{1adbc1fa40d14fbc96616c9714c00756,
title = "TH‐C‐M100J‐09: MR Guided Focused Ultrasound (MRgFU) For The Treatmentment of Prostate Cancer: A Feasibility Study of Increasing Cellular Uptake of AS‐MDM2 in Vivo",
abstract = "Purpose: MDM2 is an oncogene and overexpressed in 30–40{\%} of prostate cancer. Antisense MDM2 oligonucleotide (AS‐MDM2) inhibits MDM2 expression, and enhances the effects of radiation and chemotherapy on prostate cancer. The purpose of this study is to investigate the feasibility of increasing the cellular uptake of AS‐MDM2 using MR guided High Intensity Focused Ultrasound (MRgFU). Materials and Methods: A HIFU system (InSightec ExAblate 2000) and a 1.5T MR scanner (GE) were used for this study. Human prostate cancer cells LNCaP 105, were grown orthotopically in the prostates of 11 nude mice. Extensive experiments were performed to determine the optimal MR parameters for target delineation and the optimal ultrasound parameters for animal treatment studies using an acoustic phantom. The mice bearing implanted prostate tumors (61±22mm3) were treated under general anesthesia using pulsed focused ultrasound with the output acoustic power of 4W, pulse width of 100msec and either 300 or 900 pulses in one sonication. The focal region is cigar shaped, about 2mm in diameter and 10mm in focal length. The focal peak was set within the target under the MR guidance. Two to four sonications were used to cover the whole tumor. Immediately after the treatment 0.1ml of AS‐MDM2, dissolved in PBS, was given by tail vein injection at doses 25mg/kg. After 24hr, the animals were sacrificed and tumors were removed. The expression levels of p53 proteins were analyzed by immunohistochemical staining. Results: Our preliminary results showed that the animals tolerated well the HIFU treatment. With 300 pulses per site in each sonication blood cell extravasation on H&E staining and an increase in p53 expression (5.0±2.4{\%}) in the treated tumor bearing LNCaP cells were observed as compared to the control group (1.3 ± 0.5{\%}). Conclusion: MRgFU can be used an alternative treatment modality for prostate cancer treatment.",
author = "L. Chen and P. Hachem and A. Hananel and Z. mu and L. Padovani and C. Mercier and L. Khor and H. Kwon and C. ma and Alan Pollack",
year = "2007",
doi = "10.1118/1.2761657",
language = "English (US)",
volume = "34",
pages = "2625",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "6",

}

TY - JOUR

T1 - TH‐C‐M100J‐09

T2 - MR Guided Focused Ultrasound (MRgFU) For The Treatmentment of Prostate Cancer: A Feasibility Study of Increasing Cellular Uptake of AS‐MDM2 in Vivo

AU - Chen, L.

AU - Hachem, P.

AU - Hananel, A.

AU - mu, Z.

AU - Padovani, L.

AU - Mercier, C.

AU - Khor, L.

AU - Kwon, H.

AU - ma, C.

AU - Pollack, Alan

PY - 2007

Y1 - 2007

N2 - Purpose: MDM2 is an oncogene and overexpressed in 30–40% of prostate cancer. Antisense MDM2 oligonucleotide (AS‐MDM2) inhibits MDM2 expression, and enhances the effects of radiation and chemotherapy on prostate cancer. The purpose of this study is to investigate the feasibility of increasing the cellular uptake of AS‐MDM2 using MR guided High Intensity Focused Ultrasound (MRgFU). Materials and Methods: A HIFU system (InSightec ExAblate 2000) and a 1.5T MR scanner (GE) were used for this study. Human prostate cancer cells LNCaP 105, were grown orthotopically in the prostates of 11 nude mice. Extensive experiments were performed to determine the optimal MR parameters for target delineation and the optimal ultrasound parameters for animal treatment studies using an acoustic phantom. The mice bearing implanted prostate tumors (61±22mm3) were treated under general anesthesia using pulsed focused ultrasound with the output acoustic power of 4W, pulse width of 100msec and either 300 or 900 pulses in one sonication. The focal region is cigar shaped, about 2mm in diameter and 10mm in focal length. The focal peak was set within the target under the MR guidance. Two to four sonications were used to cover the whole tumor. Immediately after the treatment 0.1ml of AS‐MDM2, dissolved in PBS, was given by tail vein injection at doses 25mg/kg. After 24hr, the animals were sacrificed and tumors were removed. The expression levels of p53 proteins were analyzed by immunohistochemical staining. Results: Our preliminary results showed that the animals tolerated well the HIFU treatment. With 300 pulses per site in each sonication blood cell extravasation on H&E staining and an increase in p53 expression (5.0±2.4%) in the treated tumor bearing LNCaP cells were observed as compared to the control group (1.3 ± 0.5%). Conclusion: MRgFU can be used an alternative treatment modality for prostate cancer treatment.

AB - Purpose: MDM2 is an oncogene and overexpressed in 30–40% of prostate cancer. Antisense MDM2 oligonucleotide (AS‐MDM2) inhibits MDM2 expression, and enhances the effects of radiation and chemotherapy on prostate cancer. The purpose of this study is to investigate the feasibility of increasing the cellular uptake of AS‐MDM2 using MR guided High Intensity Focused Ultrasound (MRgFU). Materials and Methods: A HIFU system (InSightec ExAblate 2000) and a 1.5T MR scanner (GE) were used for this study. Human prostate cancer cells LNCaP 105, were grown orthotopically in the prostates of 11 nude mice. Extensive experiments were performed to determine the optimal MR parameters for target delineation and the optimal ultrasound parameters for animal treatment studies using an acoustic phantom. The mice bearing implanted prostate tumors (61±22mm3) were treated under general anesthesia using pulsed focused ultrasound with the output acoustic power of 4W, pulse width of 100msec and either 300 or 900 pulses in one sonication. The focal region is cigar shaped, about 2mm in diameter and 10mm in focal length. The focal peak was set within the target under the MR guidance. Two to four sonications were used to cover the whole tumor. Immediately after the treatment 0.1ml of AS‐MDM2, dissolved in PBS, was given by tail vein injection at doses 25mg/kg. After 24hr, the animals were sacrificed and tumors were removed. The expression levels of p53 proteins were analyzed by immunohistochemical staining. Results: Our preliminary results showed that the animals tolerated well the HIFU treatment. With 300 pulses per site in each sonication blood cell extravasation on H&E staining and an increase in p53 expression (5.0±2.4%) in the treated tumor bearing LNCaP cells were observed as compared to the control group (1.3 ± 0.5%). Conclusion: MRgFU can be used an alternative treatment modality for prostate cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=77949352544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949352544&partnerID=8YFLogxK

U2 - 10.1118/1.2761657

DO - 10.1118/1.2761657

M3 - Article

AN - SCOPUS:77949352544

VL - 34

SP - 2625

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 6

ER -